Clinical Trials

SB 9200

Spring Bank successfully completed a Phase 1 SAD/MAD study of SB 9200 in healthy HCV infected patients in 2014 looking at safety and antiviral efficacy of single oral doses of SB 9200 between 100 mg and 900 mg once a day. The data from this Phase 1 study was presented at the 2015 EASL meeting.

In June 2016, we initiated a Phase 2a clinical trial of SB 9200 in non-cirrhotic patients with chronic Hepatitis B virus (HBV) to explore both monotherapy and combination therapy with a direct-acting antiviral (DAA). We anticipate topline data from this trial in the second quarter of 2017.